The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

The AR-V7 abnormality takes place more often among patients who’ve undergone multiple lines of hormone therapies. Scientists believe that the AR-V7 abnormality is definitely triggered by chronic low testosterone levels and may be an adaptive response of the cancer tumor to keep up AR signaling when the normal AR is inhibited.. AR-V7 status does not affect response to taxane chemotherapy in individuals with mCRPC Findings from a small prospective study claim that androgen receptor V7 status does not significantly affect response to taxane chemotherapy in males with metastatic castration-resistant prostate tumor .Provided the truncated duration of the trial and the number of adjudicated events , and assuming no change in any of the original assumptions, we estimated the conditional power of the trial to be significantly less than 40 percent. Although sufferers treated with bardoxolone methyl experienced a significant increase in the approximated GFR, as compared with those that received placebo, there is a significantly higher incidence of heart failure and of the composite end result of nonfatal myocardial infarction, nonfatal stroke, hospitalization for center failure, or death from cardiovascular causes in the bardoxolone methyl group.